On March Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, reported that it will present preclinical data for OTX-2002, the Company’s lead drug candidate for the treatment of hepatocellular carcinoma (HCC), at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022 (Press release, Omega Therapeutics, MAR 8, 2022, View Source [SID1234609722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These preclinical data highlight the potential of epigenetic modulation of the c-MYC (MYC) oncogene as a promising new approach for the treatment of hepatocellular carcinoma (HCC), where MYC over expression is associated with aggressive disease in up to 70% of HCC cases," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "While MYC represents an attractive therapeutic target, it has historically been considered undruggable, due to the consistent failure of current modalities to inhibit MYC directly or indirectly. We look forward to sharing these data that support the potential of epigenetic modulation using our platform to systematically control the underlying biology of gene expression and remain on track to file an Investigational New Drug application for OTX-2002 in the first half of 2022."

Details for the AACR (Free AACR Whitepaper) Annual Meeting 2022 poster presentation are as follows:

Title: Epigenetic modulation of the MYC oncogene as a potential novel therapy for HCC
Abstract #: 2629
Date and Time: Tuesday, April 12, 2022 at 9:00 a.m. through 12:30 p.m. CDT

The poster will be posted to our website at View Source at the same time as the presentation.

About OTX-2002

OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of hepatocellular carcinoma (HCC). OTX-2002 is designed to modulate levels of c-MYC (MYC) expression by utilizing targeted mRNA-encoded proteins to mediate epigenetic regulation while potentially overcoming MYC auto regulation. The MYC oncogene is associated with aggressive disease in up to ~70% of patients with HCC. Omega is currently evaluating OTX-2002 in Investigational New Drug (IND)-enabling studies.

On March 8, 2022 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported the upcoming presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 of pre-clinical data for ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory Acute Myeloid Leukemia (AML) (Press release, Arcellx, MAR 8, 2022, View Source [SID1234609721]). ACLX-002 can be activated in a dose dependent manner in vivo with soluble protein adapters allowing for controllability and adaptability to address intra-and inter-patient disease heterogeneity and off-target antigen expression that are often associated with serious dose-limiting adverse events in AML.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Presentation are as Follows:

Session Category: Immunology
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Sunday, April 10, 2022, 1:30 PM – 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Board Number: 22
Permanent Abstract Number: 587

On March 8, 2022 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and best-in-class allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," reported it will present additional pre-clinical data on the company’s CBL-B program in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, LA (Press release, HotSpot Therapeutics, MAR 8, 2022, View Source [SID1234609720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: A novel allosteric CBL-B inhibitor with differentiated immune enhancing activity in preclinical models
Session Category: Immunology
Session Title: Immune Checkpoints
Session Date and Time: Sun., Apr. 10, 2022, 1:30-5:00 PM ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Poster Board Number: 8
Abstract Number: 598

On March 8, 2022 Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that new preclinical data on its small-molecule Wee1 inhibitors will be presented during a poster session at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in New Orleans, Louisiana, April 8-13, 2022 (Press release, Schrodinger, MAR 8, 2022, View Source [SID1234609719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle, allowing time for DNA repair before cell division takes place. Inhibition of Wee1 allows for accumulation of DNA damage, triggering DNA breakage and apoptosis in tumor cells. Data from third party clinical studies are showing promising anti-tumor activity in solid tumors, including ovarian and uterine cancer. Schrödinger has identified multiple highly selective Wee1 inhibitors with optimized physicochemical properties that show strong pharmacodynamic responses and anti-tumor activity in preclinical models. This potentially best-in-class profile may position these structurally distinct Wee1 inhibitors for applications both as monotherapy and as combination therapy with other agents. Schrödinger expects to select a Wee1 development candidate later this year.

Details of the poster presentation are as follows:

Title: Discovery of potent, selective, and orally available Wee1 inhibitors that demonstrate increased DNA damage and mitosis in tumor cells leading to tumor regression in vivo
Abstract number: 2570
Date & time: Tuesday, April 12, 9:00 a.m – 12:30 p.m. CDT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 21

On March 8, 2022 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4, has been selected for an oral presentation at the upcoming 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 8-13, 2022 in New Orleans, LA (Press release, Bicycle Therapeutics, MAR 8, 2022, View Source [SID1234609718]). The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details

Title: BT8009-100 Phase I/II Study of Novel Bi-Cyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression
Abstract #: 7971
Presenter: Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology
Session Title: Biomarker Advances in Clinical Trials
Date/Time: Sunday, April 10, 2022 at 4:00 p.m. ET

Poster Presentation Details

Title: Development of a CD137 Receptor Occupancy Assay to Support the Phase I/II Study of BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA)
Abstract #: 5555
Presenter: Heather Cohen, Bicycle Therapeutics
Session Title: Immune Response to Therapies / Immune Monitoring and Clinical Correlates
Date/Time: Monday, April 11, 2022 at 2:30 p.m. ET

Title: Activity of the Erythropoietin-Producing Hepatocellular A2 Receptor (EphA2) Targeting Bicycle Toxin Conjugate (BTC) BCY6033 in EGFR Inhibitor Resistant Non-Small Lung Cancer (NSCLC) Patient Derived Xenografts
Abstract #: 333
Presenter: Kenneth Ngo, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
Session Title: Biological Therapeutic Agents and Novel Drugs
Date/Time: Sunday, April 10, 2022 at 2:30 p.m. ET

Title: Modeling the cDC1 Ex Vivo and In Vitro: Development and Characterization of a Conventional Dendritic Cell Culture System to Support Drug Discovery
Abstract #: 4230
Presenter: Laura Goodfield, Bicycle Therapeutics
Session Title: Immunomodulatory Agents and Interventions 3
Date/Time: Wednesday, April 13, 2022 at 10:00 a.m. ET

Title: Generation of a Bicycle NK-TICA, a Novel NK Cell Engaging Molecule Designed to Induce Targeted Tumor Cytotoxicity
Abstract #: 4233
Presenter: Fay Dufort, Bicycle Therapeutics
Session Title: Immunomodulatory Agents and Interventions
Date/Time: Wednesday, April 13, 2022 at 10:00 a.m. ET

The posters and a copy of the presentation will be available on the Publications section of bicycletherapeutics.com following presentation.

Conference Call Details

Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m. ET to review the data being presented. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.